Immunotherapy combo shows promise in battling esophageal cancer before surgery
NCT ID NCT06952621
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for people with resectable locally advanced esophageal squamous cell carcinoma. About 390 participants will be randomly assigned to receive either toripalimab plus nab-paclitaxel and platinum, or a standard chemo regimen (docetaxel, cisplatin, 5-fluorouracil). The main goal is to see if the new combination leads to a higher rate of complete tumor disappearance after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tangdu Hospitial, Xi'an, Shaanxi Rrovince
Xi'an, Shaanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return